TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04326062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Main Study
Description: The pharmacist will participate in the management of repeat prescribing and undertake medication reviews (which will address high risk prescribing and potentially inappropriate prescribing, deprescribing and cost-effective and generic prescribing) with adult patients. Pharmacists will also provide prescribing advice regarding the use of preferred drugs, undertake clinical audits, join practice team meetings and facilitate practice-based education. Throughout the six-month intervention period, anonymised practice-level medication (e.g. medication changes) and cost data will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROM Study
Description: For this, a sub-set of patients (n=200) aged ≥65 years on ≥10 repeat medicines will be recruited and invited to a medication review with the pharmacist. PROMs and healthcare utilisation data will be collected using patient questionnaires and a six-week follow-up review with these patients will also be conducted.
Study: NCT02224534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
Study: NCT03761472

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid injection
Description: Hyaluronic acid 48 mg 2.0% in 2.4 ml solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich plasma injection
Description: Platelet-rich plasma injection 5ml
Study: NCT02115113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
Study: NCT02224534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
Study: NCT02278640

Intervention type: DEVICE
Group type: OTHER
Intervention: Harmonic ACE®+7 Shears
Description: Vessel/pedicle sealing performance assessed for transection and sealing of the of the uterine vasculature.
Study: NCT03041935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ilioinguinal/iliohypogastric nerve block
Description: See arm description

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal-epidural nerve block
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: See arm description
Study: NCT02912598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mallinckrodt™ Endobronchial Tube
Study: NCT03041935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: See arm description
Study: NCT03098368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigotine
Study: NCT03041935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: See arm description
Study: NCT02912598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fuji Uniblocker™
Study: NCT03098368

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of rotigotine patch
Study: NCT01017146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene foam
Description: Tazarotene foam once a day application to the face
Study: NCT02912598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView VivaSight™-SL+EB
Study: NCT03041935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: See arm description
Study: NCT00882024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: 150 mg tranilast tablets, bid, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: 75 mg tablets, bid, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, bid, 12 weeks
Study: NCT00947128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
Study: NCT01010607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration and Mirror
Description: 10 treatments of 30 minutes in which vibration of 50-100 Hz will be administrated to the elbow and wrist muscles together with the use of a mirror. The patient moves his healthy hand in a certain repetitive pattern and watches its reflection on a mirror. Meanwhile he receives vibration in his affected hand in a timing that induces the illusion of movements similar to the movements of his healthy hand, thereby inducing a strong illusion of movement of his affected hand.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: 10 sessions of mirror therapy: moving the healthy hand while watching its reflection on a mirror. Meanwhile sham vibration over bone in the affected handwill be given to resemble the conditions of the experimental arm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: no mirror, sham vibration
Description: 10 sessions in which patient moves his healthy hand and tries to move his affected hand, which is hidden by an opaque board instead of a mirror. Sham vibration is applied to bone instead of muscle, no illusion is generated.
Study: NCT02605408

Intervention type: DEVICE
Intervention: LenSx® laser system
Description: Femtosecond laser system used for cornea incision, capsulotomy and lens fragmentation during cataract surgery

Intervention type: PROCEDURE
Intervention: Phacoemulsification
Description: Removal of the cataractous lens
Study: NCT03381287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801 Tablets, 500 mg
Description: 500 mg/day (250 mg BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801 Tablets, 1000 mg
Description: 1000 mg/day (500 mg BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801 Tablets, 2000 mg
Description: 2000 mg/day (1000 mg BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match 500 mg HTD1801
Description: 2 tablets/day (1 tablet BID)
Study: NCT04119544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation
Description: upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
Study: NCT02912598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COOK© Arndt Endobronchial Blocker
Study: NCT04083898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab will be administered on a 28-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab will be administered on a 28-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab will be administered on a 28-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab will be administered on a 28-day cycle
Study: NCT03381287

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match 1000 mg HTD1801
Description: 4 tablets/day (2 tablet BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match 2000 mg HTD1801
Description: 8 tablets/day (4 tablet BID)
Study: NCT03744338

Intervention type: OTHER
Intervention: questionnaire
Description: The questionnaire is composed of two parts:~The first part let know the characteristics of the patients as age, the BMI, the socio-professional category, the current treatments, the medical-surgical antecedents of interest.
Study: NCT00207220

Intervention type: PROCEDURE
Intervention: arterial tonometry
Description: used to determine peripheral arterial vascular tone by measuring blood pressure waveforms via a probe attached to the finger.

Intervention type: PROCEDURE
Intervention: echocardiography
Description: ultrasound test using sound waves to create a moving picture of the heart
Study: NCT00873275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 5mg/kg IV day 1 and 15 of each 28 day course of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Leucovorin, 5-FU and Oxaliplatin
Study: NCT04083898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered on a 28-day cycle as follows

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered on a 28-day cycle as follows

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered on a 28-day cycle as follows

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered on a 28-day cycle as follows

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered on a 28-day cycle as follows

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered on a 28-day cycle as follows

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered on a 28-day cycle as follows

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered on a 28-day cycle as follows
Study: NCT04119544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intensive Visual Simulation
Description: * First week: observation, mentalization and then attempt to perform the movements on the screen.~* Second and third weeks: production of analytical movements of wrist flexion/extension, pronation/supination, finger flexion/extension, thumb opposition.~* From the 4th week until the end: depending on the patient's motor capacities, continuation of the work of the previous 2 weeks or introduction of more functional work with object manipulation, gripping work.~Conventional rehabilitation upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
Study: NCT03471520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Earplugs and eye masks
Description: Patients in this study will be given earplugs and eye masks to be worn during sleep
Study: NCT03727230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: Transfusion with RhD+ blood product rather than rare RhD-negative blood to Asian-type DEL recipients
Study: NCT00873275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 400 mg/m2 IV bolus immediately following leucovorin on days 1 and 15 of a 28 day course of treatment. Then 2.4 gm/m2 IV continuous infusion over 46 hours immediately following bolus dose on days 1 and 2 and 15 and 16 of a 28 day course of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 400 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodiol
Description: Dose escalation in cohorts (3 patients/cohort) from an initial dose of 125 mg PO BID through 625 mgs PO BID beginning on Day -6 from infusion of bevacizumab and FOLFOX continuing for the duration of the treatment.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Analysis on discard tissues

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Determined in normal and malignant tissues in patients who undergo surgical resection after treatment on this trial

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Analysis on discard tissues

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Determined on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Performed on tumor blocks from the primary and the metastases from the patients on study
Study: NCT01812486

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: dose de escalation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard dose
Study: NCT04545788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.
Description: AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.
Description: AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.
Description: AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.
Study: NCT03372629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID-085
Description: Hard gelatin capsules for oral administration formulated in strengths of 10 mg, 100 mg, and 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID-085
Description: Hard gelatin capsules for oral administration formulated in strengths of 10 mg, 100 mg, and 200 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules matching ID-085 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules matching ID-085 capsules
Study: NCT01780909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin Sulfate Fasted State

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin Sulfate Fed State
Study: NCT03214146

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYNRCS-Allo inj
Description: The patients enrolled in the trial will be successively allocated into single cohort for HYNRCS-Allo inj., 1.0 X 10\^6 cells/kg according to the protocol design.
Study: NCT01017146

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam once a day application to the face
Study: NCT03739593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-1105-CF1
Description: AR-1105 clinical formulation 1 (AR-1105-CF1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-1105-CF2
Description: AR-1105 clinical formulation 2 (AR-1105-CF2)
Study: NCT01780909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin Sulfate w/ domperidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin Sulfate w/ loperamide HCl
Study: NCT00715312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Olein
Description: A total of 70g of test oil is incorporated into cooked meal which accounts for 30-35% of calorie intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Olein
Description: A total of 70g of test oil is incorporated into cooked meal which provides 30-35% of calorie
Study: NCT03536598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10 mg + Valsartan 160 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160 mg + Rosuvastatin 20 mg
Study: NCT02573376

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Directly Observed Therapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wirelessly Observed Therapy
Study: NCT03372473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast mixed with Loratadine
Description: Montelukast 5mg mixed with Loratadine 5mg, one dose per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast 5mg
Study: NCT05798273

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intra-arterial injection
Description: All patients will receive an intravenous injection of \[68Ga\]Ga-PSMA-11 (1.5 MBq/kg), followed by a synchronous PET/MRI scan (median duration approximately 50 min) at 45-60 min post-injection.~In case of a positive \[68Ga\]Ga-PSMA-PET signal at the tumor site, patients will return (in 2 weeks) for an intra-arterial injection (i.e., a neuro-interventional procedure) of 68Ga-PSMA-11 (1.5 MBq/kg), followed by a repeat synchronous PET/MRI scan (median duration 50 min) at 45-60 min post-injection.
Study: NCT02287129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 50 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m2
Study: NCT05798273

Intervention type: DEVICE
Group type: OTHER
Intervention: synchronous PET/MRI scan
Description: Scan done at (median duration approximately 50 min) at 45-60 min post-injection.

Intervention type: OTHER
Group type: OTHER
Intervention: Radiopharmacon Contrast agent
Description: Type: \[68Ga\]Ga-PSMA-11 dosage: 1.5 MBq/kg
Study: NCT02287129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 625 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 200 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 200 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 2 mg/ml min
Study: NCT02022072

Intervention type: DEVICE
Group type: OTHER
Intervention: measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)
Description: measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)
Study: NCT02287129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: total dosage 41,4 Gy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: translational analysis
Study: NCT00261807

Intervention type: DRUG
Group type: OTHER
Intervention: Daptomycin 6mg/kg/day
Study: NCT04568044

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Peripheral blood sample will be obtained.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Peripheral blood sample will be obtained.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Peripheral blood sample will be obtained.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Peripheral blood sample will be obtained.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Peripheral blood sample will be obtained.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Peripheral blood sample will be obtained.
Study: NCT02548416

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positive end-expiratory pressure
Description: Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium.~As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure is set to 6 or 8 cm H20 (8 if BMI\>25) in the intervention group.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group, zero PEEP
Description: Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Zero PEEP is used.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.